---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-207854"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-08-27T23:59:59+00:00"
generated_at: "2026-05-31T07:26:04.347385+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics CSO departs, CFO role changed, Executive Chairman resigns amid strategic pivot

## Summary
- Valerie Morisset, EVP R&D and CSO, separated August 23; settlement provides 18 months base salary, pro rata bonus, accelerated equity vesting.
- Company shifts focus to autoimmune-driven inflammatory diseases (budoprutug) and ceases UK operations.
- Brett Kaplan appointed principal financial officer after Andrew Levin resigns as Executive Chairman; Levin remains Chairman.
- Levin continues as director and Chairman of Board; Kaplan's COO role unchanged.

## SEC filing metadata
- accession: 0001193125-24-207854
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-08-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/0001193125-24-207854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/d884075d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-207854
- JSON: https://secwatch.observer/filing/0001193125-24-207854.json
- Plain text: https://secwatch.observer/filing/0001193125-24-207854.txt

## Key facts
- Executive change
  Brett Kaplan was appointed as principal financial officer at Climb Bio, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: On August 26, 2024, the Board of Directors of the Company (the “Board”) appointed Brett Kaplan, the Company’s Chief Operating Officer, to serve as principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/0001193125-24-207854-index.htm
- Executive change
  Andrew Levin was appointed as Chairman of the Board at Climb Bio, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: The appointment was made in connection with Andrew Levin’s resignation from his role as Executive Chairman of the Company. Dr. Levin continues to serve as a director of the Company and was appointed Chairman of the Board in connection with his resignation as Executive Chairman.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/0001193125-24-207854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.